160 related articles for article (PubMed ID: 31138700)
21. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
22. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
Baertsch MA; Leber MF; Bossow S; Singh M; Engeland CE; Albert J; Grossardt C; Jäger D; von Kalle C; Ungerechts G
Cancer Gene Ther; 2014 Sep; 21(9):373-80. PubMed ID: 25145311
[TBL] [Abstract][Full Text] [Related]
24. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
25. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
[TBL] [Abstract][Full Text] [Related]
26. Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?
Bots STF; Hoeben RC
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650405
[TBL] [Abstract][Full Text] [Related]
27. Measles virus for cancer therapy.
Russell SJ; Peng KW
Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
[TBL] [Abstract][Full Text] [Related]
28. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.
Vijayakumar G; Zamarin D
Methods Mol Biol; 2020; 2058():133-154. PubMed ID: 31486036
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
30. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.
Bian H; Wilden H; Fournier P; Peeters B; Schirrmacher V
Int J Oncol; 2006 Dec; 29(6):1359-69. PubMed ID: 17088973
[TBL] [Abstract][Full Text] [Related]
31. Primary resistance phenomena to oncolytic measles vaccine viruses.
Noll M; Berchtold S; Lampe J; Malek NP; Bitzer M; Lauer UM
Int J Oncol; 2013 Jul; 43(1):103-12. PubMed ID: 23612727
[TBL] [Abstract][Full Text] [Related]
32. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection.
Hong CS; Fellows W; Niranjan A; Alber S; Watkins S; Cohen JB; Glorioso JC; Grandi P
Gene Ther; 2010 Oct; 17(10):1200-5. PubMed ID: 20463757
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2.
Wang Y; Zhou X; Wu Z; Hu H; Jin J; Hu Y; Dong Y; Zou J; Mao Z; Shi X; Huo Y; Lyu J; Fang Z; Zhang W; Zhu Y; Li B; Liu B
Hum Gene Ther; 2019 May; 30(5):651-660. PubMed ID: 30499341
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
35. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
36. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
Yoo JY; Kim JH; Kwon YG; Kim EC; Kim NK; Choi HJ; Yun CO
Mol Ther; 2007 Feb; 15(2):295-302. PubMed ID: 17235307
[TBL] [Abstract][Full Text] [Related]
37. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
[TBL] [Abstract][Full Text] [Related]
38. Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma.
Lal S; Raffel C
Methods Mol Biol; 2022; 2423():165-177. PubMed ID: 34978698
[TBL] [Abstract][Full Text] [Related]
39. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
40. Imaging of viral thymidine kinase gene expression by replicating oncolytic adenovirus and prediction of therapeutic efficacy.
Kim EJ; Yoo JY; Choi YH; Ahn KJ; Lee JD; Yun CO; Yun M
Yonsei Med J; 2008 Oct; 49(5):811-8. PubMed ID: 18972602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]